B-Cell Malignant Neoplasm — Trials

B-Cell Malignant Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

7,466 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 2,083
Recruiting: 1,077
Ph III recruiting: 121
Growth YoY: +2.3%
Industry share: 26%
Top sponsor: National Cancer Institute (NCI)
Termination share: 35.1%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (1,167)

clinicaltrialsPublishedShowing 101–150 of 1,285 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06465316	Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma	recruiting	Phase 1	26	National Cancer Institute (NCI)NIH	1	Sep 22, 2026	clinicaltrials
NCT07095452	A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant	recruiting	Phase 2 / Phase 3	680	AbbVieINDUSTRY	4